RecruitingRecruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287 · Pfizer
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER
About this study
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.
To join the study, participants must meet the following conditions:
* Are aged 18 years or older
* Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)
* Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)
* Have healthy organs based on medical tests and are in good physical condition
After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.
Eligibility criteria
Inclusion Criteria:
* Male or female participants aged ≥18 years at the time of informed consent.
* Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
* Participants have not received systemic therapy for T-SCLC.
* Have at least one measurable lesion as the target lesion based on RECIST v1.1.
* Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Have a minimum life expectancy of \>12 weeks.
* Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
* Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter \<1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.
* Leptomeningeal disease
* Clinically significant risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula
* History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)
* Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)
* History of allogeneic organ or hematopoietic stem cell transplantation
* Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)
* Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:
* Prior or current non-infectious pneumonitis requiring systemic therapy
* DLCO \<50% predicted
* Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement
* Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose
* Baseline QTcF \>480 msec
* Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study
* Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage
* History of significant bleeding disorders or recent major bleeding events
* Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding
* Active, uncontrolled, or symptomatic infection, including:
* Active TB
* Active hepatitis B or C
* Uncontrolled HIV infection
* History of immunodeficiency
* Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies
* Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation
* Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods
* Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes
* Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)
* Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements
Study design
Enrollment target: 40 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-07-02
Estimated completion: 2031-03-24
Last updated: 2026-11-20
Interventions
Drug: PF-08634404Drug: Chemotherapy
Primary outcomes
- • Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (From start of treatment until first documented CR or PR (approximately maximum up to 1 years))
- • Number of Participants with Adverse Events (AEs) (Up to 90 days after the last dose of treatment)
Sponsor
Pfizer · industry
Contacts & investigators
ContactPfizer CT.gov Call Center · contact · ClinicalTrials.gov_Inquiries@pfizer.com · 1-800-718-1021
InvestigatorPfizer CT.gov Call Center · study_director, Pfizer
All locations (75)
City of Hope National Medical CenterRecruiting
Duarte, California, United States
UC San Diego Medical Center - EncinitasRecruiting
Encinitas, California, United States
City of Hope Lennar Foundation Cancer CenterRecruiting
Irvine, California, United States
UC San Diego Koman Family Outpatient PavilionRecruiting
La Jolla, California, United States
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)Recruiting
La Jolla, California, United States
UC San Diego Moores Cancer CenterRecruiting
La Jolla, California, United States
UC San Diego Sulpizio Cardiovascular CenterRecruiting
La Jolla, California, United States
UC San Diego Medical Center - Bankers HillRecruiting
San Diego, California, United States
UC San Diego McGrath Outpatient Pavilion - HillcrestRecruiting
San Diego, California, United States
UC San Diego Medical Center- HillcrestRecruiting
San Diego, California, United States
UC San Diego Medical Center - Rancho BernardoRecruiting
San Diego, California, United States
UC San Diego Medical Center - VistaRecruiting
Vista, California, United States
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical CenterRecruiting
Coral Gables, Florida, United States
Sylvester Comprehensive Cancer Center- DoralRecruiting
Doral, Florida, United States
Sylvester Comprehensive Cancer CenterRecruiting
Miami, Florida, United States
University of Miami Hospital and ClinicsRecruiting
Miami, Florida, United States
Sylvester Comprehensive Cancer Center- KendallRecruiting
Miami, Florida, United States
Sylvester Comprehensive Cancer Center - Sole MiaRecruiting
North Miami, Florida, United States
Hope and Healing Clinical ResearchRecruiting
Hinsdale, Illinois, United States
Hope and Healing Clinical ResearchRecruiting
New Lenox, Illinois, United States
Brigham and Women's HospitalNot Yet Recruiting
Boston, Massachusetts, United States
Dana-Farber Cancer InstituteNot Yet Recruiting
Boston, Massachusetts, United States
Dana-Farber Cancer Institute -Chestnut HillNot Yet Recruiting
Newton, Massachusetts, United States
MSK Basking RidgeRecruiting
Basking Ridge, New Jersey, United States
MSK MonmouthRecruiting
Middletown, New Jersey, United States
MSK Bergen.Recruiting
Montvale, New Jersey, United States
MSK CommackRecruiting
Commack, New York, United States
MSK WestchesterRecruiting
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center - Investigational Drug Service PharmacyRecruiting
Long Island City, New York, United States
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).Recruiting
New York, New York, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
MSK NassauRecruiting
Uniondale, New York, United States
University Hospitals Cleveland Medical CenterNot Yet Recruiting
Cleveland, Ohio, United States
Westmead HospitalRecruiting
Westmead, New South Wales, Australia
Calvary Connery CentreRecruiting
Elizabeth Vale, South Australia, Australia
Warringal Private HospitalRecruiting
Heidelberg, Victoria, Australia
Hospital Beneficência Portuguesa de São PauloRecruiting
São Paulo, São Paulo, Brazil
Hospital São Lucas da PUCRSRecruiting
Porto Alegre, Brazil
Hospital Sírio LibanêsRecruiting
São Paulo, Brazil
Centro Paulista de Oncologia ClínicaRecruiting
São Paulo, Brazil
Peking Union Medical College HospitalRecruiting
Beijing, Beijing Municipality, China
Fujian Cancer HospitalRecruiting
Fuzhou, Fujian, China
Henan Cancer HospitalRecruiting
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and TechnologyRecruiting
Wuhan, Hubei, China
The First Affiliated Hospital of Nanchang UniversityRecruiting
Nanchang, Jiangxi, China
Shanghai Chest HospitalRecruiting
Shanghai, Shanghai Municipality, China
The first Affiliated Hospital, Zhejiang University School of MedicineRecruiting
Hangzhou, Zhejiang, China
Zhejiang Cancer HospitalRecruiting
Hangzhou, Zhejiang, China
Centre Léon BérardRecruiting
Lyon, France
Assistance Publique Hôpitaux de Marseille - Hôpital NordRecruiting
Marseille, France
Prince of Wales HospitalRecruiting
Hong Kong, Hong Kong
Queen Mary HospitalRecruiting
Hong Kong, Hong Kong
Caritas Hospital and Institute of Health SciencesRecruiting
Kottayam, Kerala, India
Tata Memorial HospitalRecruiting
Mumbai, Maharashtra, India
Rajiv Gandhi Cancer Institute And Research CentreRecruiting
New Delhi, National Capital Territory of Delhi, India
Sheba Medical CenterRecruiting
Ramat Gan, HA Merkaz, Israel
Shaare Zedek Medical CenterRecruiting
Jerusalem, Jerusalem, Israel
IRCCS Istituto Nazionale dei Tumori Regina ElenaRecruiting
Roma, ROME, Italy
A.O.U. San Luigi GonzagaRecruiting
Orbassano, Turin, Italy
Cliniche Gavazzeni S.p.A. - Humanitas GavazzeniRecruiting
Bergamo, Italy
Aichi Cancer Center HospitalRecruiting
Nagoya, Aichi-ken, Japan
Okayama University HospitalRecruiting
Kita, Okayama-ken, Japan
Kansai Medical University HospitalRecruiting
Hirakata, Osaka, Japan
National Cancer Center - Tsukiji CampusRecruiting
Chūō, Tokyo, Japan
Japanese Foundation for Cancer ResearchRecruiting
Kotoku, Tokyo, Japan
Osaka International Cancer Institute(OICI)Recruiting
Osaka, Japan
Hospital Clínic de BarcelonaNot Yet Recruiting
Barcelona, Catalunya [cataluña], Spain
Institut Català d'Oncologia - L'HospitaletRecruiting
L'Hospitalet de Llobregat, Catalunya [cataluña], Spain
Hospital Universitario La PazNot Yet Recruiting
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario 12 de OctubreRecruiting
Madrid, Spain
Hospital Universitario Virgen Del RocioRecruiting
Seville, Spain
National Cheng Kung University HospitalRecruiting
Tainan, Taiwan
National Taiwan University HospitalRecruiting
Taipei, Taiwan
National Taiwan University Cancer Center (NTUCC)Recruiting
Taipei, Taiwan
Taipei Veterans General HospitalRecruiting
Taipei, Taiwan